Authored By: Sarah
11 Jul 2024

 Amyotrophic Lateral Sclerosis Treatment Market Size to grow by USD 663.7 million between 2024-2028

According to a research report “ Amyotrophic Lateral Sclerosis Treatment Market” by Type (Intravenous, Oral) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 663.7 million, at a CAGR of  12.79% during the forecast period. The Amyotrophic Lateral Sclerosis (ALS) market size is projected to grow due to the rising incidence and prevalence of this debilitating neurological condition. ALS, also known as Lou Gehrig's disease, is a progressive and fatal neuromuscular disorder with no known cure. Approximately 5-10% of cases are hereditary, referred to as Familial ALS. In the US, the prevalence of ALS in 2022 was 5.5 cases per 100,000 persons, with a higher occurrence among white men, non-Hispanics, and individuals aged 60-69 years. Conversely, the lowest number of cases were reported in those aged 18-39 years. This increasing demographic trend underscores the significant market potential for innovative therapeutic solutions in the ALS treatment landscape.

Browse market data tables, figures, and in-depth TOC on “Amyotrophic Lateral Sclerosis Treatment Market” by Type (Intravenous, Oral) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the Intravenous segment is projected to dominate the market size in 2024

Hospital pharmacies serve as crucial intermediaries in the healthcare industry, procuring, storing, and selling pharmaceutical products for the treatment of both outpatients and inpatients. These products, which include therapeutic and critical care drugs, play a significant role in the management of various conditions, including Amyotrophic Lateral Sclerosis (ALS). As hospitals expand their reach through acquisitions and partnerships with physician practices, hospital pharmacies have emerged as the preferred distribution channel for compounded drugs. The increasing influence of hospitals in the healthcare landscape will continue to drive demand for pharmaceutical products within these institutions during the forecast period.

By Distribution Channel, Hospital pharmacies  segment is expected to hold the largest market size for the year 2024

The Amyotrophic Lateral Sclerosis (ALS) treatment market is poised for significant expansion due to the rising prevalence of this debilitating neurological condition. According to the Centers for Disease Control and Prevention (CDC), the prevalence of ALS in the US is approximately 5.2 cases per 100,000 people, translating to 16,583 identified cases in 2021. With approximately 30,000 new diagnoses each year, the market for ALS treatments is set to experience substantial growth. Notably, most ALS cases are sporadic, but 5%-10% are familial, and 20% involve a mutation of the SOD1 gene. This expanding patient population underscores the urgent need for effective treatments and therapies, thereby fueling market growth.

North America is forecasted to hold the largest market size by region in 2024

The North American Amyotrophic Lateral Sclerosis (ALS) treatment market is predominantly driven by the US, with major industry players such as Pfizer, Sangamo Therapeutics, and Celgene leading the market. These companies, with a significant presence in the US and Canada, invest heavily in research and development, as well as marketing and patient awareness initiatives. For instance, Mitsubishi Tanabe Pharma America announced positive 24-week results from a global Phase 3 open-label study on investigational oral Edaravone's safety and tolerability in ALS treatment. The study showed a favorable safety profile. The Amyotrophic Laternal Sclerosis Association, based in the US, annually spearheads initiatives to boost public awareness of ALS.

The Amyotrophic Lateral Sclerosis Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AB Science SA
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aquestive Therapeutics Inc.
  • Biogen Inc.
  • Brainstorm Cell Therapeutics Inc.
  • CORESTEM Inc.
  • Cytokinetics Inc.
  • Denali Therapeutics Inc.
  • Dr Reddys Laboratories Ltd.
  • Eledon Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • Italfarmaco Holding SPA
  • Medindia Health
  • Mitsubishi Chemical Group Corp.
  • Otsuka Holdings Co. Ltd.
  • Revalesio Corp.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Treeway BV
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disorder affecting the central nervous system that leads to the progressive degeneration and death of motor neuron cells. This condition results in the loss of voluntary muscle function, leading to a stationary lifestyle and eventual respiratory failure. The incidence rate of ALS is approximately 2-5 cases per 100,000 people per year, with higher rates in the geriatric population. ALS can be categorized into familial and sporadic types, with gene mutations and infection rates being potential causes. Despite the availability of drug therapies like Riluzole and Edaravone, the expensive treatment options for ALS can be a significant burden for patients and their families. Drug therapies like Ursodoxicoltaurine are under investigation for their potential benefits. Awareness about ALS is essential to early diagnosis and effective treatment. ALS patients can access medications through online providers, retail pharmacies, and hospital pharmacies. Women and Men are equally affected, with no known gender preference. The disease affects the voluntary muscles, leading to muscle weakness, twitching, and atrophy. The condition is not contagious, and there is currently no cure for ALS. Glutamate, a neurotransmitter, plays a role in the disease's progression. The disease can lead to respiratory failure, making it crucial to manage symptoms effectively.

Market Research Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disorder affecting nerve cells in the central nervous system, leading to voluntary muscle weakness and eventual paralysis. With an incidence rate of 2-5 cases per 100,000 people, ALS has limited treatment options and high healthcare expenditure. The market for ALS treatments is growing due to the urgent need for effective medications. Companies like NeuroSense Therapeutics are focusing on developing biomarkers for early diagnosis and genetics-based drug therapies. Seed funding and reimbursement scenarios are crucial factors in bringing these expensive treatments to the population, especially those with familial and sporadic types of ALS. ALS drugs such as immunosuppressants and Ursodoxicoltaurine are currently available, but awareness about ALS remains less than other conditions. Healthcare infrastructure and access to medications vary, with online providers, retail pharmacies, and hospital pharmacies offering different options. Speech and physical therapy are essential components of ALS treatment, along with medical technology and medication. The geriatric population, including women and men, is most affected by ALS, with respiratory failure being a common cause of death. The infection rates of ALS are not well understood, but gene mutation and glutamate imbalance are believed to play a role. The search for new drug therapies and alternative treatments like stem cell therapies continues.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document